Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Thursday, October 19th, RTT News reports. Shareholders of record on Tuesday, November 28th will be given a dividend of 0.84 per share on Tuesday, December 12th. This represents a $3.36 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend is Monday, November 27th.
Johnson & Johnson has increased its dividend payment by an average of 6.7% per year over the last three years and has raised its dividend every year for the last 54 years. Johnson & Johnson has a dividend payout ratio of 46.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $7.85 per share next year, which means the company should continue to be able to cover its $3.36 annual dividend with an expected future payout ratio of 42.8%.
Shares of Johnson & Johnson (NYSE:JNJ) traded down $1.05 during trading hours on Thursday, hitting $140.01. 4,713,146 shares of the stock traded hands, compared to its average volume of 5,871,537. The firm has a market cap of $375,226.25, a P/E ratio of 19.56, a PEG ratio of 2.84 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52 week low of $109.93 and a 52 week high of $144.35.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.68 EPS. equities research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Winch Advisory Services LLC boosted its position in Johnson & Johnson by 1.4% in the second quarter. Winch Advisory Services LLC now owns 4,379 shares of the company’s stock worth $579,000 after purchasing an additional 60 shares during the last quarter. Stanley Laman Group Ltd. lifted its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 7,789 shares of the company’s stock valued at $1,030,000 after buying an additional 102 shares during the last quarter. Apriem Advisors lifted its position in shares of Johnson & Johnson by 6.3% during the 2nd quarter. Apriem Advisors now owns 2,597 shares of the company’s stock valued at $344,000 after buying an additional 155 shares during the last quarter. Wayne Hummer Investments L.L.C. raised its stake in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Wayne Hummer Investments L.L.C. now owns 23,120 shares of the company’s stock valued at $3,059,000 after purchasing an additional 208 shares during the period. Finally, Halbert Hargrove Russell LLC raised its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after purchasing an additional 15 shares during the period. 65.90% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts recently issued reports on JNJ shares. J P Morgan Chase & Co boosted their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group set a $145.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Cowen set a $147.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. UBS restated an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 1st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $144.59.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Plans Quarterly Dividend of $0.84” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2017/12/07/johnson-johnson-jnj-to-issue-quarterly-dividend-of-0-84-on-december-12th-updated-updated.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.